Inventor · disambiguated record
Laurent H. Boissel
Also filed as: BOISSEL LAURENT · BOISSEL LAURENT H
32 granted patents·18 pending applications·153 citations·filing 2016–2025
97Inventor score
Top patents by PatentIndex Score
50 records- 0197US11230699B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsNANTKWEST INC·Filed 2020·Granted Jan 25, 2022·9 cites·27 claims
- 0297US11207350B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2021·Granted Dec 28, 2021·11 cites·11 claims
- 0397US11000550B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2020·Granted May 11, 2021·6 cites·9 claims
- 0496US11077143B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsNANTKWEST INC·Filed 2019·Granted Aug 3, 2021·16 cites·9 claims
- 0595US12384852B2Genetically modified NK-92 cells having a safety switchIMMUNITYBIO INC·Filed 2021·Granted Aug 12, 2025·2 cites·20 claims
- 0695US12109238B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2022·Granted Oct 8, 2024·2 cites·17 claims
- 0795US11547727B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Jan 10, 2023·10 cites·13 claims
- 0895US10960024B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Mar 30, 2021·17 cites·18 claims
- 0995US10765701B2Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cellsNANTKWEST INC·Filed 2019·Granted Sep 8, 2020·7 cites·25 claims
- 1095US10456420B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2016·Granted Oct 29, 2019·19 cites·11 claims
- 1194US12492377B2Modified NK-92 haNK003 cells for the clinicIMMUNITYBIO INC·Filed 2023·Granted Dec 9, 2025·1 cites·19 claims
- 1294US11643452B2Fc-epsilon carIMMUNITYBIO INC·Filed 2021·Granted May 9, 2023·6 cites·8 claims
- 1393US12403178B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2023·Granted Sep 2, 2025·2 cites·22 claims
- 1493US11207392B2Coordinated multi-prong cancer therapyNANT HOLDINGS IP LLC·Filed 2017·Granted Dec 28, 2021·5 cites·15 claims
- 1593US11129850B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Sep 28, 2021·8 cites·4 claims
- 1693US11058723B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Jul 13, 2021·8 cites·7 claims
- 1793US10736921B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2019·Granted Aug 11, 2020·5 cites·12 claims
- 1892US10774310B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2019·Granted Sep 15, 2020·4 cites·11 claims
- 1991US11071774B2Nant cancer vaccineNANT HOLDINGS IP LLC·Filed 2020·Granted Jul 27, 2021·2 cites·16 claims
- 2090US12365874B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsIMMUNITYBIO INC·Filed 2021·Granted Jul 22, 2025·1 cites·18 claims
- 2189US12473348B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 2289US12473347B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 2388US10801013B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2018·Granted Oct 13, 2020·2 cites·14 claims
- 2488US2025340664A1Genetically modified nk-92 cell lineIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 2587US12435122B2Fc-epsilon CARIMMUNITYBIO INC·Filed 2019·Granted Oct 7, 2025·3 cites·8 claims
- 2687US11813292B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2019·Granted Nov 14, 2023·2 cites·3 claims
- 2786US12378300B2Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cellsIMMUNITYBIO INC·Filed 2020·Granted Aug 5, 2025·1 cites·19 claims
- 2886US11753625B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2020·Granted Sep 12, 2023·1 cites·18 claims
- 2983US12180283B2Anti-B7-H4 chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Dec 31, 2024·1 cites·21 claims
- 3080US2025073305A1Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)IMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3177US2025066484A1Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3276US2024366972A1Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3376US2024252540A1Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironmentIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3475US11439697B2Nant cancer vaccineNANTCELL INC·Filed 2021·Granted Sep 13, 2022·0 cites·20 claims
- 3575US2025270282A1Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cellsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 3674US2023272042A1Fc-epsilon carIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 3768US12498363B2Combined invasion and cytotoxicity assay using chemokine secreting target cellsNANTKWEST INC·Filed 2019·Granted Dec 16, 2025·0 cites·13 claims
- 3868US2025154465A1Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptorsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 3967US11992504B2Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironmentIMMUNITYBIO INC·Filed 2020·Granted May 28, 2024·0 cites·11 claims
- 4062US2023034802A1Nant Cancer VaccineNANTCELL INC·Filed 2022·Application pending·0 cites
- 4158US2024042023A1Fc-Receptor CAR Constructs and CellsIMMUNITYBIO INC·Filed 2021·Application pending·0 cites
- 4256US11221328B2Hypoxic NK cells and methods thereforNANTCELL INC·Filed 2018·Granted Jan 11, 2022·0 cites·4 claims
- 4354US2021169931A1Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selectionNANTKWEST INC·Filed 2020·Application pending·0 cites
- 4453US2025298030A1Compositions and Methods for NK-92 Cells Expressing Native CD16IMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 4552US2022017594A1Il-2 dependent nk-92 cells with stable fc receptor expressionNANTKWEST INC·Filed 2019·Application pending·0 cites
- 4652US2021040175A1Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validationNANTKWEST INC·Filed 2020·Application pending·0 cites
- 4751US2023172982A1Elimination of BCMA-positive malignancies by CAR expressing NK cellsIMMUNITYBIO INC·Filed 2020·Application pending·0 cites
- 4848US2020171087A1Methods for treating merkel cell carcinoma (mcc) using nk-92 cellsNANTKWEST INC·Filed 2018·Application pending·0 cites
- 4947US2021187024A1NK-92 Cells to Stimulate Anti-Cancer VaccineNANTKWEST INC·Filed 2018·Application pending·0 cites
- 5042US2020121720A1Nk-92 cells and il-15 agonist combination therapyNANTKWEST INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laurent H. Boissel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →